المؤلفون: Forster, Martin, Hackshaw, Allan, De Pas, Tommaso, Cobo, Manuel, Garrido, Pilar, Summers, Yvonne, Dingemans, Anne-Marie C., Flynn, Michael, Schnell, David, von Wangenheim, Ute, Loembe, Arsene-Bienvenu, Kaiser, Rolf, Lee, Siow Ming

المصدر: Forster , M , Hackshaw , A , De Pas , T , Cobo , M , Garrido , P , Summers , Y , Dingemans , A-M C , Flynn , M , Schnell , D , von Wangenheim , U , Loembe , A-B , Kaiser , R & Lee , S M 2018 , ' A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3) ' , Lung Cancer , vol. 120 , pp. 27-33 . https://doi.org/10.1016/j.lungcan.2018.03.007

مصطلحات موضوعية: Nintedanib, Non-small cell lung cancer, Squamous, TRIPLE ANGIOKINASE INHIBITOR, CLINICAL-PRACTICE GUIDELINES, LABEL DOSE-ESCALATION, BIBF 1120, CONTROLLED-TRIAL, CARBOPLATIN, PACLITAXEL, BEVACIZUMAB, PHARMACOKINETICS, ANGIOGENESIS

الاتاحة: https://cris.maastrichtuniversity.nl/en/publications/259dbe45-c141-426d-a7ce-06df734f1edc
https://doi.org/10.1016/j.lungcan.2018.03.007
http://discovery.ucl.ac.uk/10047686/1/Forster%20M%20et%20al%20LUME-Lung%203_Lung%20Cancer.pdf

المؤلفون: Woodcock, HV, Molyneaux, PL, Maher, TM

المصدر: 510 ; 503

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Chemistry, Medicinal, Pharmacology & Pharmacy, interstitial lung disease, BIBF 1120, clinical trials, usual interstitial pneumonia, acute exacerbation, TRIPLE ANGIOKINASE INHIBITOR, FIBROBLAST-GROWTH-FACTOR, PLACEBO-CONTROLLED TRIAL, LABEL DOSE-ESCALATION, TYROSINE KINASE INHIBITOR, ADVANCED SOLID TUMORS, I OPEN-LABEL, PHASE-I, TGF-BETA, Phase II as Topic, Humans, Idiopathic Pulmonary Fibrosis, Indoles, Lung, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Receptors, Platelet-Derived Growth Factor, Vascular Endothelial Growth Factor

Relation: Drug Design, Development and Therapy; http://hdl.handle.net/10044/1/63032; https://dx.doi.org/10.2147/DDDT.S38833

الاتاحة: http://hdl.handle.net/10044/1/63032
https://doi.org/10.2147/DDDT.S38833

المؤلفون: Philip L. Molyneaux, Hannah V. Woodcock, Toby M. Maher

المصدر: Drug Design, Development and Therapy

مصطلحات موضوعية: Oncology, Indoles, Pharmaceutical Science, Chemistry, Medicinal, Review, Pharmacology, PLACEBO-CONTROLLED TRIAL, Tyrosine-kinase inhibitor, Idiopathic pulmonary fibrosis, chemistry.chemical_compound, Usual interstitial pneumonia, Drug Discovery, Pulmonary fibrosis, Receptors, Platelet-Derived Growth Factor, Pharmacology & Pharmacy, usual interstitial pneumonia, BIBF 1120, I OPEN-LABEL, Lung, FIBROBLAST-GROWTH-FACTOR, interstitial lung disease, biology, Interstitial lung disease, TGF-BETA, ErbB Receptors, Vascular endothelial growth factor, PHASE-I, LABEL DOSE-ESCALATION, ADVANCED SOLID TUMORS, Nintedanib, TYROSINE KINASE INHIBITOR, Life Sciences & Biomedicine, Platelet-derived growth factor receptor, medicine.medical_specialty, medicine.drug_class, Clinical Trials, Phase II as Topic, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, acute exacerbation, TRIPLE ANGIOKINASE INHIBITOR, clinical trials, Science & Technology, business.industry, medicine.disease, Idiopathic Pulmonary Fibrosis, respiratory tract diseases, Receptors, Vascular Endothelial Growth Factor, chemistry, biology.protein, 1115 Pharmacology And Pharmaceutical Sciences, Receptor, Epidermal Growth Factor, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3263f94e79c02f19d180cea9b79114e
http://hdl.handle.net/10044/1/63032